Mezagitamab (TAK-079) is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.
|Developed By||Takeda Oncology|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
November 13, 2019
In the 14 patients receiving at least 4 cycles of therapy by the time of the data cutoff, the objective response rate (ORR; partial response or better) was 43%, 1 patient's response deepened over time to VGPR, the clinical benefit rate (minimal response or better) was 57%. Within this group, in patients never exposed to anti-CD38 therapy, the ORR was 46%.
There are no resources, links or videos to display for this treatment.
SparkCures is working closely with Takeda Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners